Image commercially licensed from: Unsplash
Dr. Erik Goluboff was born in Brooklyn, New York. He attended Columbia College, Columbia University, where he took Biology. He graduated 1986 magna cum laude. He then attended Johns Hopkins University School of Medicine in 1990. On January 2015, he was the valedictorian of the Executive MBA Program at Stern School of Business, New York University in New York.
From 1990 to 1991, he spent a year as a surgical intern at Johns Hopkins Hospital in Baltimore, Maryland. He was a surgical resident at the Columbia-Presbyterian Medical Center in New York. He enrolled in the Urology residency program at Columbia-Presbyterian Medical Center and stayed there for four years.
Between 1996 and 2002, Dr Erik Goluboff worked as an Assistant Attending the Department of Urology at the Columbia Presbyterian Medical Center. In 1998, he was appointed Director of Urology at the Allen Pavilion of the Columbia Presbyterian Medical Center, a position he held until 2011. In addition, the Columbia Presbyterian Medical Center designated him as Director of the Residents’ Clinic in 1998, and he held that position until 2011.
He spent the previous five years, up to 2007, working as an Associate Attending at New York Presbyterian Hospital’s Presbyterian Campus. Between 2007 and 2011, he served in an additional appointment at New York Presbyterian Hospital’s Presbyterian Campus. He began his position at Beth Israel Medical Center in 2011 and remained there until 2020.
Learn More About Dr. Eric Goluboff
Dr. Erik Goluboff joined AstraZeneca in June 2020 as Global Clinical Product Lead Imfinzi for their late-stage research and development activities in bladder cancer after over 30 years as an academic urologic oncologist. He was allowed to become the Global Clinical Head for Imfinzi. He formerly held the position of Professor of Urology at Mount Sinai’s Icahn School of Medicine.
He earned an MBA with concentrations in corporate finance, financial instruments, and management at NYU’s Stern School of Business. He formerly held the positions of Clinical Urology Professor at Columbia University College of Physicians and Surgeons and Director of Urology at New York-Presbyterian Hospital/The Allen Pavilion. He received the honors of Magna cum laude, Phi Beta Kappa, and Alpha Omega Alpha from Columbia College of Columbia University and the Johns Hopkins University School of Medicine, respectively.
He trained in general surgery for a year at Johns Hopkins before completing his surgical and urology residencies at Columbia. A Valentine Fellowship from the New York Academy of Medicine and a Young Investigator Award from the American Society of Clinical Oncology funded his subsequent urologic oncology fellowship at Columbia. During his fellowship, he then received extra training in the detection and management of urologic malignancies such as prostate, bladder, kidney, penis, and testis.
In his current role at Genentech/Roche, Dr. Erik Goluboff serves as the Principal Medical Lead for urologic malignancies. In this capacity, he is involved in the therapeutic development program for bladder, kidney, and prostate tumors. Dr. Goluboff has been in practice as a urologist for nearly three decades and has held several roles of increasing responsibility during his career.
Other Notable Activities Of Dr. Goluboff
During his decades of urology practice, Dr. Goluboff has been honored with several accolades, including the Young Investigator Award from the National Kidney Foundation, First Prize Laboratory Investigation in the Valentine Essay Contest held by the New York Academy of Medicine, Honorable Mention in the Valentine Essay Contest held by the New York Academy of Medicine, and the Pfizer Scholar in Urology Award (twice).
He has completed over 3000 surgical procedures, including over 1000 radical prostatectomies for the treatment of prostate cancer, using either open or robotic surgical methods. Dr. Goluboff has produced over 150 publications (some of which are included below), and he has been involved in a large number of clinical studies with novel medications for the treatment of urologic conditions.
Aside from this, Dr. Erik Goluboff is also an experienced professor. At New York’s Columbia University, he oversaw the urology clinic. He also surgically and medically cared for thousands of individuals with urologic oncology issues. He studied urologic conditions extensively and wrote over 150 papers on the subject. He was actively active in the urology community by reviewing articles for and serving on the editorial boards of many publications.
Conclusion
At Genentech/Roche, Dr. Erik Goluboff serves as the Principal Medical Lead for urologic malignancies. In this role, he is involved in the company’s therapeutic development program for cancers affecting the bladder, kidneys, and prostate. It’s been nearly three decades since he started his career as a urologist, and he’s received many awards and commendations for his work.
After completing an internship in general surgery at Johns Hopkins for a year, he then went on to complete residencies in both surgical and urological specialties at Columbia University. Dr. Goluboff spent more than 30 years working in academic urology before accepting a position with AstraZeneca as the Global Clinical Product Lead for Imfinzi. This role is responsible for the company’s late-stage research and development activities in bladder cancer.
